DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 14707266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement

  2003cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.

  2001cited by this paper
• Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

  2000cited by this paper
• Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes

  1999influential reference
• Roles of Replication Protein A and DNA-dependent Protein Kinase in the Regulation of DNA Replication following DNA Damage*

  1999cited by this paper
• Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis.

  1999cited by this paper
• The ATM protein is required for sustained activation of NF-κB following DNA damage

  1999cited by this paper
• Competitive and noncompetitive inhibition of the DNA-dependent protein kinase.

  1999cited by this paper
• A phosphatidylinositol 3‐kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation

  1998cited by this paper
• DNA end-joining: from yeast to man.

  1998cited by this paper
• Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity.

  1998cited by this paper
• DNA end-joining catalyzed by human cell-free extracts.

  1998cited by this paper
• A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination.

  1998cited by this paper
• Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.

  1997cited by this paper
• DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus

  1997cited by this paper
• In Vivo Methods for Screening and Preclinical Testing

  1997cited by this paper
• Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells.

  1996cited by this paper
• The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.

  1996cited by this paper
• Loss of the catalytic subunit of the DNA-dependent protein kinase in DNA double-strand-break-repair mutant mammalian cells.

  1995cited by this paper
• DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product.

  1995cited by this paper
• Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation.

  1995cited by this paper
• Human DNA-activated protein kinase (DNA-PK) is homologous to phosphatidylinositol kinases.

  1995cited by this paper
• Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line

  1995cited by this paper
• The viridin family of steroidal antibiotics.

  1995cited by this paper
• Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

  1994cited by this paper
• A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

  1994cited by this paper
• Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.

  1993cited by this paper
• The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen.

  1993cited by this paper
• Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II.

  1992cited by this paper
• The SCID mouse mutant: definition, characterization, and potential uses.

  1991cited by this paper
• A link between double-strand break-related repair and V(D)J recombination: the scid mutation.

  1991cited by this paper
• scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair.

  1991cited by this paper
• Radiation and chemotherapy sensitizers and protectors.

  1990cited by this paper
• The scid mutation in mice causes a general defect in DNA repair

  1990cited by this paper
• Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen

  1990cited by this paper
• Mechanisms of bleomycin-induced DNA degradation

  1987cited by this paper
• Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.

  1985cited by this paper
• DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

  1983cited by this paper
• Radiobiology for the radiologist

  1973cited by this paper

• Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers

  2024cites this paper
• Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy

  2022influential citation
• Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer.

  2021cites this paper
• Targeting DNA repair pathway in cancer: Mechanisms and clinical application

  2021cites this paper
• Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

  2021cites this paper
• Molecular basis of human ATM kinase inhibition

  2021cites this paper
• GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer.

  2020cites this paper
• DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR

  2020cites this paper
• Targeting DNA-PK in cancer.

  2020cites this paper
• DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions.

  2020influential citation
• Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through non-homologous end joining

  2020cites this paper
• Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR).

  2020cites this paper
• Retraction Retracted: Apoptosis and Molecular Targeting Therapy in Cancer

  2020cites this paper
• Inhibitors of DNA Double-Strand Break Repair at the Crossroads of Cancer Therapy and Genome Editing.

  2020cites this paper
• Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.

  2019cites this paper
• Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.

  2019cites this paper
• Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia

  2019influential citation
• Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models

  2019cites this paper
• RPA1 downregulation enhances nasopharyngeal cancer radiosensitivity via blocking RAD51 to the DNA damage site

  2018cites this paper
• Cancer II

  2018cites this paper
• Targeting DNA-PK as a Therapeutic Approach in Oncology

  2018cites this paper
• Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family

  2017cites this paper
• Rational design, synthesis, pharmacophore modeling, and docking studies for identification of novel potent DNA-PK inhibitors.

  2017cites this paper
• Radiosensitizing activity of novel small molecule BRCA1 and DNA-PK inhibitors in lung and colon carcinoma

  2017cites this paper
• Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy

  2017cites this paper
• 1,3,5‐Trisubstituted Pyrazoles as Potent Negative Allosteric Modulators of the mGlu2/3 Receptors

  2017cites this paper
• Targeting DNA‐Dependent Protein Kinase for Cancer Therapy

  2017cites this paper
• Small molecule inhibitors of DNA-PK for tumor sensitization to anticancer therapy.

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• DNA‐PK activity is associated with caspase‐dependent myogenic differentiation

  2016cites this paper
• Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells

  2016cites this paper
• An Approach to Breast Cancer Immunotherapy: The Apoptotic Activity of Recombinant Anti‐Interleukin‐6 Monoclonal Antibodies in Intact Tumour Microenvironment of Breast Carcinoma

  2016cites this paper
• APRIN(PDS5B) et PALB2, deux protéines impliquées dans la réparation de l'ADN par recombinaison homologue et l'apparition de cancers

  2016cites this paper
• Sensitization strategies in lung cancer

  2016cites this paper
• Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar; 160(1)

  2016cites this paper
• Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy

  2015cites this paper
• Silencing NFBD1/MDC1 enhances the radiosensitivity of human nasopharyngeal cancer CNE1 cells and results in tumor growth inhibition

  2015cites this paper
• Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.

  2015cites this paper
• Analysis and characterization of chemo- and radiation therapy sensitizing strategies in tumours with focus on effects of phenothiazines on DNA damage response signalling

  2015cites this paper
• DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

  2015cites this paper
• Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.

  2014cites this paper
• Delineation of key XRCC4/Ligase IV interfaces for targeted disruption of non‐homologous end joining DNA repair

  2014cites this paper
• Apoptosis and Molecular Targeting Therapy in Cancer

  2014cites this paper
• Hypoxia-directed drug strategies to target the tumor microenvironment.

  2014cites this paper
• A Preclinical Study Combining the DNA Repair Inhibitor Dbait with Radiotherapy for the Treatment of Melanoma

  2014cites this paper
• Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents.

  2014influential citation
• Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

  2014cites this paper
• Inhibition of DNA Repair as a Therapeutic Target

  2014cites this paper
• Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors

  2013cites this paper
• Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

  2013influential citation
• Analysis of telomere length and function in radiosensitive mouse and human cells in response to DNA-PKcs inhibition

  2013cites this paper
• DEVELOPMENT OF A HYPOXIA ACTIVATED PRODRUG FOR THE SELECTIVE INHIBITION OF DNA-DEPENDENT PROTEIN KINASE by JORDAN DARICE CRAN

  2013influential citation
• Radiosensitization Strategies Through Modification of DNA Double-Strand Break Repair

  2013influential citation
• Gene therapy and cell reprogramming in mouse models of monogenic hematopoietic stem cell diseases

  2013cites this paper
• DNA-PK in CLL Chemotherapy

  2013cites this paper
• Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond

  2012cites this paper
• Molecular characterization of phenothiazines in experimental cancer therapy - New tricks of an old drug revealed

  2012cites this paper
• Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

  2012cites this paper
• Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621

  2012cites this paper
• Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment.

  2012cites this paper
• Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer

  2012cites this paper
• Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.

  2012cites this paper
• Small molecules targeting phosphoinositide 3-kinases

  2012cites this paper
• DNA Damage and Cellular Stress Responses Effect of the Inositol Polyphosphate InsP 6 on DNA-PK – Dependent Phosphorylation

  2011cites this paper
• DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

  2011cites this paper
• Dérivés de quinazoline

  2011cites this paper
• Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells

  2011cites this paper
• Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?

  2011cites this paper
• Targeting the DNA double strand breaks repair for cancer therapy.

  2010cites this paper
• DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells.

  2010cites this paper
• Repair of Clustered DNA Lesions in Double Strand Break Repair Deficient Human Tumor Cells

  2010cites this paper
• DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.

  2010cites this paper
• Controlling the Mdm2-Mdmx-p53 Circuit

  2010cites this paper
• Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes

  2010cites this paper
• DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis

  2010cites this paper
• Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK).

  2010cites this paper
• Phosphorylation of ATM/ATR substrates in eukaryotic cells after infection with Helicobacter pylori

  2010cites this paper
• Small-Molecule Drugs Mimicking DNA Damage: A New Strategy for Sensitizing Tumors to Radiotherapy

  2009cites this paper
• 3D-QSAR studies on a series of inhibitors docked into a new homology model of the DNA-PK receptor.

  2009cites this paper
• Small-Molecule DrugsMimicking DNADamage: ANew Strategy for SensitizingTumors to Radiotherapy

  2009cites this paper
• Telomere Dysfunction and the DNA Damage Response

  2009cites this paper
• The development of hypoxia activated DNA repair inhibitors

  2009cites this paper
• Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice.

  2009cites this paper
• Acute and Late Biologic Effects of Radiation Therapy in the Management of Childhood Cancer

  2008cites this paper
• Endosomal Translocation of CpG-Oligodeoxynucleotides Inhibits DNA-PKcs-Dependent IL-10 Production in Macrophages1

  2008cites this paper
• Current concepts for the combined treatment modality of ionizing radiation with anticancer agents.

  2007cites this paper
• Activation of telomerase by ionizing radiation: differential response to the inhibition of DNA double-strand break repair by abrogation of poly (ADP-ribosyl)ation, by LY294002, or by Wortmannin.

  2007cites this paper
• Neue Konzepte und Substanzen zur Radiosensibilisierung

  2007cites this paper
• Non-homologous DNA end joining in anticancer therapy.

  2007cites this paper
• Chemically targeting the PI3K family.

  2007cites this paper
• Therapeutic potential of drugs to modulate DNA repair in cancer

  2007cites this paper
• Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

  2007cites this paper
• Involvement of single- and double-strand break repair processes in beta-lapachone-induced cell death.

  2007cites this paper
• Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.

  2007cites this paper
• Chlorambucil Cytotoxicity in Malignant B Lymphocytes Is Synergistically Increased by 2-(Morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-Mediated Inhibition of DNA Double-Strand Break Repair via Inhibition of DNA-Dependent Protein Kinase

  2007cites this paper
• The biology of Ku and its potential oncogenic role in cancer.

  2006cites this paper
• Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.

  2006cites this paper
• The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy.

  2006cites this paper
• Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

  2006cites this paper
• Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage

  2006cites this paper